{"id":"W3011361209","doi":"10.1136/jitc-2020-000530","title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nausea; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Tolerability; Antibody; Lung cancer; Oncology; Population; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001678028,0.001460201,0.001528732,0.0003923917,0.0004138779,0.0006902326,0.0006443501,0.0008763353,0.002556538],"category_scores_gemma":[0.0008856825,0.0005597515,0.001016963,0.0003143223,0.000774541,0.0006805249,0.0003307349,0.003491574,0.0006841032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008663404,"about_ca_system_score_gemma":0.001400266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006089758,"about_ca_topic_score_gemma":0.001071094,"domain_scores_codex":[0.9995787,0.000190298,0.00002034332,0.00007437969,0.00004773629,0.0000885515],"domain_scores_gemma":[0.9993261,0.0001247117,0.0001137725,0.00006836069,0.00005065893,0.0003164954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4540673,0.2262675,0.02059254,0.001054781,0.001424893,0.0006918402,0.0008945968,0.005735398,0.1120412,0.0003565274,0.007368842,0.1695045],"study_design_scores_gemma":[0.3789334,0.5914332,0.01809499,0.00002268703,0.0002659811,0.000471134,0.00004298908,0.001512108,0.005809317,0.0001959374,0.00318945,0.00002875756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996062,0.0007394303,0.0005123816,0.0002580913,0.000049038,0.001178196,0.0004337815,0.0000572371,0.0007099414],"genre_scores_gemma":[0.9921217,0.0007037473,0.002058634,0.0006996525,0.0001170483,0.001356933,0.001590847,0.0000257238,0.001325646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002556538,"threshold_uncertainty_score":0.008874416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02102198637447333,"score_gpt":0.3722325480268819,"score_spread":0.3512105616524085,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}